0001209191-14-046952.txt : 20140714 0001209191-14-046952.hdr.sgml : 20140714 20140714160427 ACCESSION NUMBER: 0001209191-14-046952 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140710 FILED AS OF DATE: 20140714 DATE AS OF CHANGE: 20140714 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walsh Jeffrey T. CENTRAL INDEX KEY: 0001578251 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 14973747 MAIL ADDRESS: STREET 1: C/O BLUEBIRD BIO, INC. STREET 2: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-07-10 0 0001293971 bluebird bio, Inc. BLUE 0001578251 Walsh Jeffrey T. C/O BLUEBIRD BIO, INC. 150 SECOND STREET CAMBRIDGE MA 02141 0 1 0 0 Chief Operating Officer Common Stock 2014-07-10 4 M 0 7500 2.09 A 7500 D Common Stock 2014-07-10 4 S 0 7500 33.20 D 0 D Stock Option (right to buy) 2.09 2014-07-10 4 M 0 7500 0.00 D 2021-07-13 Common Stock 7500 184307 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2013. The range of prices for the transaction reported on this line was $32.81 to $33.53. The average weighted price was $33.2023. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vests over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter. /s/ Jason F. Cole, Attorney-in-Fact 2014-07-14